首页> 外文期刊>Journal of Gastrointestinal Oncology >The impact of BMI extremes on disease-free survival and overall survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
【24h】

The impact of BMI extremes on disease-free survival and overall survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

机译:BMI极限对细胞减灭术和腹膜内高温化疗后无病生存和总体生存的影响

获取原文
获取外文期刊封面目录资料

摘要

Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are increasingly being offered to patients with peritoneal carcinomatosis (PC). On the other hand, the prevalence of obesity is also increasing and expected to reach unprecedented rates in the upcoming decades. Therefore, managing patients on either extreme of the body mass index (BMI) range is anticipated to become a routine challenge and it becomes imperative to understand the impact of BMI, as a spectrum, on the long-term outcomes of CRS and HIPEC. We aim to study the short and long-term outcomes of CRS and HIPEC in patients on both extremes of the BMI spectrum. Methods: Patients with PC who underwent CRS and HIPEC over 10 years for ovarian, colorectal, and pseudomyxoma peritonei (PMP), and whose BMI was recorded were retrospectively included. Patients were divided based on their weight strata. The primary outcomes were disease-free survival (DFS) and overall survival (OS). Results: A total of 126 patients were included. Fifty-seven point one percent were females and mean age was 59.31±1.57 years. No difference was noted between the groups in regards to demographics, perioperative characteristics, and immediate postoperative outcomes. Underweight group had a trend toward a higher peritoneal cancer index and lower rates of complete cytoreduction. Optimum BMI for OS and DFS was in the obesity range in colorectal PC, in the overweight range in ovarian PC, and in borderline obesity in PMP. Regression analysis identified underweight as an independent risk factor for shorter DFS, whereas underweight and morbid obesity were risk factors for shorter OS, after adjustment for other factors such as incomplete cytoreduction, tumor histology, and grade. Conclusions: OS and DFS vary across the BMI strata. Ovarian PC demonstrates earlier recurrence and shorter survival, whereas colorectal PC demonstrates the “obesity paradox” as patients move into the realm of obesity. BMI extremes, low or high, generally carry a poor prognosis for OS.
机译:背景:腹膜癌(PC)患者越来越多地接受细胞减灭术(CRS)和腹膜内高温化疗(HIPEC)。另一方面,肥胖症的患病率也在增加,并有望在未来几十年达到前所未有的水平。因此,在任何一个极端的体重指数(BMI)范围内管理患者都将成为一项常规挑战,因此必须了解作为一个频谱的BMI对CRS和HIPEC长期结果的影响。我们旨在研究在BMI频谱的两个极端情况下患者的CRS和HIPEC的短期和长期结果。方法:回顾性分析10年来因卵巢,结直肠和腹膜假粘液瘤(PMP)而接受了CRS和HIPEC治疗的PC患者,并记录了其BMI。根据患者的体重分层对其进行划分。主要结果是无病生存期(DFS)和总体生存期(OS)。结果:共纳入126例患者。 57%的女性是女性,平均年龄为59.31±1.57岁。两组之间在人口统计学,围手术期特征和术后即刻结局方面无差异。体重过轻的人群有更高的腹膜癌指数和更低的完全细胞减少率。 OS和DFS的最佳BMI在结直肠PC的肥胖范围内,在卵巢PC的超重范围内以及在PMP中的临界肥胖。回归分析确定,体重不足是缩短DFS的独立危险因素,而体重过轻和病态肥胖是OS缩短的危险因素,经过其他因素(如不完全细胞减少,肿瘤组织学和分级)的调整后。结论:OS和DFS在BMI层次上有所不同。卵巢PC表现出较早的复发和较短的生存期,而结直肠PC表现出随着患者进入肥胖领域而出现的“肥胖悖论”。最低或最高的BMI极端值通常预示着OS的不良预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号